
The 6 Best Orthopedic Dog Beds For Pups Of All Ages And Sizes
The best orthopedic dog beds, from brands like Casper, Orvis and more, can protect your pup's joints ... More and help them rest more comfortably.
If you're wondering whether your dog needs better support, start by observing their sleep habits. 'Discomfort may not always be obvious," says Dr. Jennifer Bruns, veterinarian at PetSmart Veterinary Services. "Dogs may avoid their bed entirely or prefer lying on the floor if the bed is not supportive enough.' Small behavioral clues like these can reveal if your pup would benefit from an orthopedic upgrade.
To help you choose a dog bed that's right for them, we've included a range of tested and expert-approved picks, like the Orvis RecoveryZone ToughChew Couch Dog Bed, which is durable enough to survive dogs who might normally shred up a bed in days, and the Sealy Lux Pet Dog Bed, designed specifically to keep pups cool. Whatever your dog's needs, the right orthopedic bed can noticeably improve how comfortably they sleep and the ease with which they move afterward.
Casper Sleep
Type: Bolstered rectangle | Sizes: 3 | Colors: 3, including Gray, Blue and Sand | Outer material: Nylon, polyester and olefin microfiber | Inner material: Memory foam, polyurethane support foam | Washable cover: Yes
What you'll love:
Keep in mind:
Many of the dog beds we've tested feel comfortable at first but start sinking and losing their support after just a few months. Casper's bed solves this problem with two layers of foam: a sturdy polyurethane foam base that gives the bed structure and keeps your dog properly elevated, plus a memory foam layer on top that cushions joints and evenly distributes weight. Forbes Vetted senior mattress editor Bridget Chapman says her dog has slept on the Casper bed daily for more than a year, and it still feels just as firm and supportive as it did on day one. (Her pup still loves it, too.)
The Casper also has firm foam bolsters around the edges, which provide dogs with a cozy spot to rest their heads or curl up against. Its cover is soft, durable and easy to unzip and toss in the washing machine (though it does take a little more effort to get back on), and the zippers tuck neatly into hidden pockets so they won't scratch your floors.
There's also some slightly loose fabric on top, which is intentionally designed for dogs who like to paw and dig around before getting comfy; it's made from tough, bonded microfiber that doesn't easily rip, even if your pup makes digging a regular habit. (Though if something does happen, replacement covers are sold separately.) Forbes Vetted managing editor Emmy Favilla says her dog often takes advantage of this feature, happily pawing at the material before settling in for a nap. And because it has a clean, understated look, the Casper blends easily into just about any room—something our editors have appreciated after months, or even years, of having it in their homes.
FurHaven
Type: Bolstered rectangle | Sizes: 5 | Colors: 3, including Brownstone and Granite Gray | Outer material: Velvet microfiber | Inner material: Orthopedic foam (convolute, solid or memory foam) | Washable cover: Yes
What you'll love:
Keep in mind:
Orthopedic dog beds can be expensive, and if you're shopping for a puppy or an older dog, it doesn't always make sense to splurge. That's why I originally bought the FurHaven Sofa Dog Bed—and why I've repurchased it multiple times since. It's less than half the cost of many premium options (under $60 for a large size), but this bed still provides supportive cushioning that gives dogs of all ages the comfort and joint support they need. The foam isn't quite as thick or dense as pricier beds, but even after a few years, it still hasn't flattened down to the floor.
FurHaven also lets you choose from a few types of foam, including egg-crate convolute foam, solid orthopedic foam and responsive memory foam, depending on what your dog needs. I've tested multiple versions and found each comfortable and supportive enough for my 50-pound dog (and roomy enough for another 40-pound pup to squeeze in). The soft velvet-like cover washes easily, hides fur very well and hasn't ripped after countless cycles in my machine. Putting the bolsters and foam back inside after cleaning does take a little patience, but that's pretty typical for washable dog beds.
Amazon
Type: Bolstered rectangle | Sizes: 5 | Colors: 3, including Autumn Brown, Modern Gray and Navy | Outer material: Faux-felt polyester | Inner material: Quad-layer memory foam and cooling gel | Washable cover: Yes
What you'll love:
Keep in mind:
If your dog overheats easily or struggles to settle comfortably, a cooling orthopedic bed might be particularly beneficial. The Sealy Lux Pet Dog Bed has a four-layer foam design specifically meant to keep dogs cooler and relieve pressure from sensitive joints. The top layer uses cooling gel to draw heat away from your dog's body, which makes a noticeable difference in warm weather. Beneath that, a memory foam layer contours to your dog's shape, and supportive foam underneath keeps your dog elevated off the floor.
Another helpful feature is the charcoal-infused bottom layer, which is designed to absorb pet odors and keep the bed fresher between washes. When it is time to clean the bed, the polyester cover zips off easily and can be tossed directly into the washing machine. This bed also has bolstered edges on three sides, giving pups a comfortable place to rest their heads or curl up against something supportive. Meanwhile, the open front makes it easy for older pets, dogs with joint pain or pups recovering from injuries to step in without extra effort.
Amazon
Type: Bolstered rectangle | Sizes: 8 | Colors: 36 (though not all colors are available in every size), including Gray, Brown and Navy | Outer material: Flannel or plush flannel | Inner material: Egg-crate orthopedic foam | Washable cover: Yes
What you'll love:
Keep in mind:
Smaller dogs often prefer beds that feel cozy and secure but aren't challenging to climb into. Bedsure's Orthopedic Dog Bed is a great pick for little pups because of its lower entry point and small front opening, a design that makes it easy for small or senior dogs to step in and out without added effort. Its egg-crate foam base is designed to cushion joints and pressure points, so it should feel especially comfortable for older small breeds or dogs recovering from injuries.
The bed has four-sided bolsters to create a snug, enclosed space that smaller dogs often find comforting, especially if they like to curl up rather than stretch out. There's also a waterproof liner beneath the removable cover, which protects the foam if your dog has an accident or a spill happens. The soft flannel cover comes in dozens of colors and zips off easily whenever you need to wash it. And the bottom of the bed is designed to be non-slip, so it'll stay in place even on slippery hardwood floors.
Chewy
Type: Pillow with headrest | Sizes: 3 | Colors: 4, including Burgundy, Khaki and Charcoal Gray | Outer material: Microfiber | Inner material: Orthopedic foam | Washable cover: Yes
What you'll love:
Keep in mind:
If you have a big dog, you've probably noticed that most dog beds just aren't built to handle their weight. The foam usually feels supportive at first, but within a few months it flattens out and your pup ends up practically lying on the floor. The Big Barker Orthopedic Pillow Dog Bed is designed with thick, mattress-quality foam specifically designed for larger breeds—Favilla says it feels more like lying on a human mattress than a standard dog bed. (Yes, she tested it out herself.) After several months of using the Big Barker at home, her large, arthritic senior dog consistently chose this bed over all the others in the house.
Instead of sinking into the foam, large dogs stay comfortably lifted off hard surfaces, and the bed is even strong enough to support two big dogs at once; the XL size easily accommodates a couple of Labs, pit bulls or similar-sized breeds. There's also a raised pillow along one side for extra comfort, so dogs can rest their heads or lean against it without restricting how much they stretch out. Vets often recommend this type of sturdy support to help prevent joint pain, especially in bigger or older dogs.
Its microfiber cover is soft, washable and does a good job resisting muddy paw prints, slobber and fur (though, like many of our favorite beds, getting it back on after washing takes a bit of patience). Just keep in mind: This bed is substantial, both in terms of price and floor space. If your dog doesn't need quite this much room, or your home is short on extra space, a smaller option like the Casper might be a better fit.
Orvis
Type: Bolstered rectangle | Sizes: 3 | Colors: 4, including Brown and Slate | Outer material: Ripstop nylon and polyester | Inner material: Dual-layer orthopedic foam | Washable cover: Yes
What you'll love:
Keep in mind:
The Orvis RecoveryZone ToughChew Couch Dog Bed is specifically built for pups determined to rip apart everything they sleep on. Unlike typical dog beds, this one has a rugged, upholstery-grade cover reinforced with ripstop nylon beneath—similar to fabric used for backpacks or camping gear—so it's almost impossible for teeth or claws to tear through. Hidden brass zippers and built-in handles are intentionally tucked out of sight, further limiting tempting chew targets. And just in case your dog somehow does manage to chew through it, Orvis backs this bed with a no-questions-asked, money-back guarantee.
Inside, the bed is designed to provide strong orthopedic support, with a dense 4-inch foam base and an additional softer layer on top that helps ease pressure from joints and sore muscles. Solid foam bolsters around three sides create a secure space that many dogs naturally gravitate toward, while the front is open for easy access. The washable cover does a surprisingly good job at hiding fur and dirt, and there's a waterproof liner underneath so the foam won't get ruined even if your pup has an accident. It's definitely pricier than other beds, but if you're tired of tossing shredded covers into the trash, the investment makes sense.
The Forbes Vetted team is made up of pet parents who regularly research, test and recommend pet products, including the best dog beds, the best dry dog food and the best dog leashes. For this guide to the best orthopedic dog beds, we relied on firsthand experience with many of these beds, plus extensive research and consultations with veterinary experts.
To find the best orthopedic dog beds, we combined long-term personal use, in-depth product research and insights from trusted veterinary professionals to ensure each recommendation is worth your investment.
Buying an orthopedic dog bed involves more than just choosing one labeled as 'orthopedic.' To ensure your dog benefits from improved joint health and comfort, here's what veterinary experts recommend looking for.
The most important feature in an orthopedic dog bed is the foam. Look specifically for high-density memory foam or a multilayered orthopedic foam base that's firm enough to prevent sinking. Bruns says true orthopedic beds 'provide proper joint support and even weight distribution to minimize pressure points on sensitive areas like hips and elbows.' Waggel's resident veterinarian Dr. Aimee Warner adds a simple test: 'Push your hand into the foam," she says. "If it slowly comes back and maintains its shape, you're likely seeing real support and not just marketing.'
Bolstered edges around the bed, like those you see on picks like the Casper and Bedsurebeds on this list, aren't just decorative. 'Side bolsters are a welcome addition, especially for dogs who curl up or need head and neck support,' says Warner. But accessibility also matters, particularly for older or mobility-challenged pets. Bruns advises pet owners to choose a bed that's easy for dogs to step onto, noting that low-profile designs without steep edges or high bolsters minimize strain and reduce discomfort.
Orthopedic beds typically represent a bigger investment, so it's important that they're both durable and easy to clean. According to Warner, washable covers are essential—especially for older dogs prone to accidents or those recovering from procedures. 'Neglecting to seek out washable covers can be a hygiene nightmare,' she says. Look for beds with removable covers that are machine washable (like every pick on our list) and ideally water-resistant to resist drool, dirt and accidents. Regularly cleaning and occasionally rotating the bed will also help extend its lifespan and keep your dog's sleeping area clean and comfortable.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
44 minutes ago
- Medscape
Could EMR Alerts Boost Hypertension Detection?
Could a simple advisory or alert in the electronic medical record (EMR) be the key to more frequent diagnosis and effective treatment of high blood pressure (BP)? While it could help, some physicians say it's not sufficient to solve the persistent problem of hypertension. However, such alerts could be part of an effective approach to catching more cases of hypertension and helping people manage their high BP. Tackling High BP Hypertension is well-known as a 'silent killer.' Left untreated, it raises the risk for heart attack, stroke, and other life-threatening events without causing any symptoms. Hypertension is also a widespread problem. The CDC estimates that about 120 million adults in the US have high BP, defined as having a systolic BP higher than 130 mm Hg or a diastolic BP greater than 80 mm Hg (or taking medication to lower their BP). However, only about 1 in 4 adults with high BP actually have their BP under control. According to the results of a recent quality improvement study in JAMA Network Open , using technology to prompt team-based care can improve primary care hypertension control and diagnosis in the ambulatory setting. The researchers tested an intervention consisting of a high BP advisory in the EMR, along with team training, audit, and feedback. If an elevated BP reading (systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg) was entered into the EMR, the medical assistant received an advisory to recheck the patient's BP. If the BP continued to be elevated, the EMR prompted a clinician-facing advisory, along with an order panel link. 'This study demonstrates that a paired human-technology intervention focused on team-based care and EMR integration is a fruitful approach to improving population health metrics,' the authors wrote. 'Anything that is done to alert the clinician is appropriate because of clinical inertia,' said Luke Laffin, MD, co-director of the Cleveland Clinic's Center for Blood Pressure Disorders in Cleveland, Ohio. 'There's a lot of clinical inertia in hypertension care. It breaks that inertia. I'm not surprised that this intervention works.' The Value of an Alert The idea of incorporating this type of alert into the EMR system is feasible, according to Brian Barr, MD, cardiologist at the University of Maryland Medical Center and assistant professor of medicine at the University of Maryland School of Medicine in Baltimore. 'Most modern EMRs — such as Epic, Cerner, Athenahealth, and others — are equipped with customizable clinical support tools that allow for automated reminders, alerts, and health maintenance prompts,' Barr said, adding that configurations could allow for notifications for missing BP readings or lack of documentation of BP within a particular time period. Alerts could also be quite useful to busy primary care physicians who see patients for a multitude of reasons. 'It's a reminder not to get distracted by the chief complaint syndrome,' said Brent Smith, MD, a family physician in Greenville, Mississippi and member of the board of directors for the American Academy of Family Physicians. 'It forces us not to overlook hypertension when there are other things that brought them into the doctor's office.' Using this type of tool could also identify patients with multiple elevated BP readings but no formal hypertension diagnosis, said Barr. That information could also allow physicians to follow patients more closely and confirm elevated BP in multiple settings — not just in the office, according to Blair Suter, MD, cardiologist with The Ohio State University Wexner Medical Center. 'It could be the canary in the coal mine,' he said. 'It could really be the sign of things to come or to progress to.' However, healthcare organizations must also be cautious about the possibility of contributing to electronic health record alert fatigue and instead find a balance that allows the use of technology to improve patient care without increasing the alert burden on clinicians. The authors of the study also acknowledged that some clinic managers had sustainability concerns about the time needed for BP rechecks. '[A]fter the rollout, some clinics piloted scheduling patients 10 minutes ahead of the clinician visit to increase previsit time for [medical assistants] to manage this and other population health initiatives,' they wrote. 'I think that rather than just having alerts, where people tend to get alarm fatigue, it might be more useful to focus on how we're collecting the data and how reliable it is and how much of a true reflection it is of the patient's true blood pressure when they're not in the office,' said Jeremy Bock, MD, interventional cardiologist and endovascular specialist at VHC Health in Arlington, Virginia. At-Home Monitoring Indeed, even if alerts do help, the challenge of getting patients to monitor their BP regularly at home does persist. At-home checks can seem nonurgent to them, especially if they are already taking an antihypertensive medication and feel fine. Kristen Trom, DO, family physician with Inspira Health in Mullica Hill, New Jersey, said that her organization's EMR uses an alert, but it's still a challenge to get patients to monitor their BP at home and take their medication. 'Resistance to starting medication can be a major challenge,' she said. 'Many of these patients have never been on medication before and prefer not to start.' 'It's trying to find that balance between being nonintrusive and also being part of their daily routine,' said Laffin. Physicians may need to spend more time emphasizing the importance of at-home BP monitoring and ensure patients know how to do it correctly. Prevention efforts can be time-consuming, noted Bock, but they can also improve patient-provider relationships and patient satisfaction. One important element of that process is reminding patients to use a validated BP cuff. Suter recommends directing patients to the website which is also suggested by the American Heart Association. Future Possibilities Time is often the biggest impediment for primary care providers. Eventually EMRs may be configured — along with AI — to incorporate the most effective cues and advisories, and then filter the information that would be most helpful for the physician, Smith said. 'It is getting better, and it has potential for the future,' he said. Barr added that other efforts could bolster such improvements. For example, clinic-level interventions also play a major role. 'Standardized blood pressure measurement protocols, routine use of home blood pressure monitoring, automated follow-up scheduling, and nurse-led hypertension visits can all support timely diagnosis and management,' Barr said. 'Engaging patients through portal alerts, educational messaging, and self-reported blood pressure entries adds another layer of protective care. Together, these strategies help close care gaps and support earlier identification and treatment of hypertension, ultimately improving long-term cardiovascular outcomes.'
Yahoo
an hour ago
- Yahoo
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 39 million to Basilea to continue to advance the development of Basilea's novel antifungals fosmanogepix and BAL2062. This additional funding is based on the successful completion of a milestone within the 'Other Transaction Agreement' (OTA, agreement number 75A50124C00033) that was awarded on September 30, 2024, and which allows for potential funding of up to approximately USD 268 million in total to develop antifungal and antibacterial assets. David Veitch, Chief Executive Officer of Basilea, said: 'We are very pleased to receive the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. Both compounds offer a novel mechanism of action and represent new therapeutic options for patients with aspergillosis, candidiasis or other life-threatening fungal infections. These infections primarily affect patients with weakened immune systems, such as cancer or transplant patients. Infections with difficult-to-treat rare molds or with resistance to current therapies are increasing. Hence, there continues to be a high medical need for new innovative antifungals.' He added: 'This second tranche of funding within the BARDA OTA will support the ongoing phase 3 study with fosmanogepix in yeast infections and the second phase 3 study, in mold infections, which is expected to start soon. It also provides funding for the preparation for the start of the phase 2 study for our antifungal BAL2062.' The USD 39 million is in addition to the initial USD 29 million BARDA committed at the signing of the OTA in September 2024. BARDA's financial contribution is about 60% of the total costs of the supported projects over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million, over up to 12 years, if all additional options to extend the contract are exercised by BARDA, upon successful completion of pre-defined milestones, including clinical and regulatory activities. About fosmanogepix Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing and the initiation of a second phase 3 study, in the treatment of adult patients with invasive mold infections, is expected soon.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). About BAL2062 BAL2062 is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains.3 Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses.4 The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis. About invasive mold infections Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.5, 6 About invasive candidiasis Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.7 The prognosis of invasive candidiasis remains difficult, with a reported mortality rate for invasive candidiasis as high as 40%, even when patients receive antifungal therapy.8 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 FAST study (candidemia/invasive candidiasis): identifier NCT05421858; FORWARD study (invasive mold infections): identifier NCT06925321 K. J. Shaw. GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis. Journal of Fungi (Basel) 2022 (8), 909 identifier NCT02956499: M. P. Mammen, D. Armas, F. H. Hughes et al. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults. Antimicrobial Agents and Chemotherapy 2019 (63), e00969-19 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: (Accessed: July 07, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456 Attachment Press release (PDF)
Yahoo
an hour ago
- Yahoo
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the next USD 39 million to Basilea to continue to advance the development of Basilea's novel antifungals fosmanogepix and BAL2062. This additional funding is based on the successful completion of a milestone within the 'Other Transaction Agreement' (OTA, agreement number 75A50124C00033) that was awarded on September 30, 2024, and which allows for potential funding of up to approximately USD 268 million in total to develop antifungal and antibacterial assets. David Veitch, Chief Executive Officer of Basilea, said: 'We are very pleased to receive the continued funding under the OTA with BARDA to support the development of our antifungal drug candidates fosmanogepix and BAL2062. Both compounds offer a novel mechanism of action and represent new therapeutic options for patients with aspergillosis, candidiasis or other life-threatening fungal infections. These infections primarily affect patients with weakened immune systems, such as cancer or transplant patients. Infections with difficult-to-treat rare molds or with resistance to current therapies are increasing. Hence, there continues to be a high medical need for new innovative antifungals.' He added: 'This second tranche of funding within the BARDA OTA will support the ongoing phase 3 study with fosmanogepix in yeast infections and the second phase 3 study, in mold infections, which is expected to start soon. It also provides funding for the preparation for the start of the phase 2 study for our antifungal BAL2062.' The USD 39 million is in addition to the initial USD 29 million BARDA committed at the signing of the OTA in September 2024. BARDA's financial contribution is about 60% of the total costs of the supported projects over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million, over up to 12 years, if all additional options to extend the contract are exercised by BARDA, upon successful completion of pre-defined milestones, including clinical and regulatory activities. About fosmanogepix Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order.1 Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections.1 A phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis is ongoing and the initiation of a second phase 3 study, in the treatment of adult patients with invasive mold infections, is expected soon.2 Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). About BAL2062 BAL2062 is a first-in-class antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains.3 Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses.4 The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis. About invasive mold infections Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.5, 6 About invasive candidiasis Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.7 The prognosis of invasive candidiasis remains difficult, with a reported mortality rate for invasive candidiasis as high as 40%, even when patients receive antifungal therapy.8 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This ad hoc announcement can be downloaded from References K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 FAST study (candidemia/invasive candidiasis): identifier NCT05421858; FORWARD study (invasive mold infections): identifier NCT06925321 K. J. Shaw. GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis. Journal of Fungi (Basel) 2022 (8), 909 identifier NCT02956499: M. P. Mammen, D. Armas, F. H. Hughes et al. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults. Antimicrobial Agents and Chemotherapy 2019 (63), e00969-19 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: (Accessed: July 07, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456 Attachment Press release (PDF)